RADX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
RADX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock lacks a strong momentum setup, has no clear bullish proprietary trading signal today, and the technical trend remains weak. The only meaningful positive is a fresh Buy initiation from H.C. Wainwright with a $6 target, but that alone is not enough to outweigh the current bearish price structure and limited fundamental visibility. Since the user is impatient and does not want to wait for an optimal entry, the direct answer is to avoid buying now and wait for a stronger setup.
Current price is 4.308 in pre-market, below the pivot level of 4.424 and beneath near-term resistance at 4.71. The technical picture is bearish: SMA_200 > SMA_20 > SMA_5 indicates a downtrend, the MACD histogram is negative at -0.0308 though mildly contracting, and RSI_6 at 47.466 is neutral with no oversold bounce signal. The stock is trading below key resistance and has nearby support at 4.137 and 3.96. The pattern-based outlook also leans weak, with a 66.67% probability of a small decline in the next day and more meaningful downside over the next month.
["H.C. Wainwright initiated coverage with a Buy rating and a $6 price target on 2026-06-04.", "Analyst highlighted RAD 101 as relatively derisked and part of a Phase 2b imaging trial in recurrent brain metastasis.", "Pre-market pricing above 4.30 suggests some early market interest ahead of the session."]
["No news in the past week, so there is no fresh event-driven catalyst.", "Technical trend is bearish with SMA_200 > SMA_20 > SMA_5.", "MACD is still below zero and RSI is neutral, showing no strong momentum reversal.", "Hedge funds are neutral with no significant trading trends over the last quarter.", "Insiders are neutral with no significant trading trends over the last month.", "No recent congress trading data available.", "Pattern analysis suggests downside bias in the near term."]
No usable latest-quarter financial snapshot was provided, so there is not enough financial data here to assess revenue growth, profitability trends, or quarterly operating momentum.
Recent analyst tone is mildly positive: H.C. Wainwright initiated coverage on 2026-06-04 with a Buy rating and a $6 target, which is above the current pre-market price. Wall Street pros appear constructive on the pipeline story and the perceived de-risking of RAD 101, but the broader market evidence in this dataset does not confirm that optimism yet. The pros are focused on upside potential from the clinical program, while the cons are the weak price trend, lack of recent news, and absence of stronger accumulation signals.
